Lifeward Ltd., a global leader in medical technology, reported financial results for the first quarter of 2025. The company experienced a net loss of $4.8 million, or $0.46 per share, compared to a net loss of $6.3 million, or $0.73 per share, in the same period of 2024. On a non-GAAP basis, adjusted net loss was $4.6 million, or $0.44 per share, down from $5.3 million, or $0.62 per share, in the first quarter of 2024. Operating loss for the first quarter of 2025 was $4.9 million, compared to $6.5 million in the previous year. Adjusted operating loss, excluding certain items, was $4.6 million, an improvement from the $5.5 million loss in the first quarter of 2024. Operating expenses decreased to $7.0 million in the first quarter of 2025 from $7.9 million in the same period of 2024, with adjusted operating expenses at $6.8 million, down from $7.3 million. This decline in expenses was mainly due to savings from the closure of the Fremont location, resource rationalization, and lower development costs following the completion of the ReWalk 7 and AlterG NEO programs. Lifeward reported liquidity of $5.7 million in unrestricted cash and cash equivalents as of March 31, 2025, with no debt. The company anticipates a sequential decline in quarterly cash burn for the remainder of the year. Additionally, Lifeward raised $0.5 million through its ATM facility after the first quarter. For 2025, Lifeward has maintained its revenue guidance, expecting full-year revenues between $28 million and $30 million. The company also highlighted the launch of the ReWalk 7 exoskeleton in the U.S. market following FDA clearance in March. AlterG sites' closure and resource consolidation have led to improved operating expense trends, with AlterG achieving over 15% revenue growth for the second consecutive quarter.